Molecular-based Testing for Sexually Transmitted Infections Using Samples Previously Collected for Vaginitis Diagnosis

Barbara Van Der Pol, Grace Daniel, Salma Kodsi, Sonia Paradis, and Charles K. Cooper

Background. Vaginal symptoms are a leading cause of primary care visits for women. Individuals exhibiting symptoms often receive laboratory testing based on clinician-specific standards of care. Thus, women seen at a family practice clinic might only receive a vaginitis workup, whereas those seen at a sexually transmitted diseases clinic could be more likely to receive only sexually transmitted infection (STI) testing.

Methods. The likelihood of STIs was assessed in women from whom samples were tested for vaginitis using a molecular diagnostic assay. Positivity rates for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis DNA, detected using the BD MAX CT/GC/TV assay, were calculated. Concordance between the BD MAX Vaginal Panel and the BD MAX CT/GC/TV assay for detection of T. vaginalis was determined.

Results. Women with bacterial vaginosis alone or with concurrent Candida spp infections had high rates of coinfection with sexually transmitted infections (24.4%–25.7%); samples from women who were negative for vaginitis had significantly lower positivity rates (7.9%; P < .001). Trichomonas vaginalis results were concordant between the BD MAX Vaginal Panel and the BD MAX CT/GC/TV assay in 559 of 560 samples tested.

Conclusions. These data suggest, as have other studies, that women with vaginitis symptoms may be at risk for an STI. Molecular testing could provide broad diagnostic coverage for symptomatic women and improve patient management, regardless of the type of clinic in which patients are treated.

Keywords. vaginitis; sexually transmitted infection; coinfection; molecular test; diagnosis.
symptoms, whereas Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) cause cervical infection and cervicitis [8]. Thus, many practitioners in non-STD clinical settings do not consider TV to be an STI, which largely restricts diagnostic coverage to vaginitis panels.

Coinfection with BV and TV, coupled with inaccurate clinical evaluation, renders the correct diagnosis of vaginal infection difficult [9]. Laboratory methods such as Gram stain and culture may be highly subjective to sampling, transport conditions, and technical proficiency, and may have prolonged turnaround times. The BD MAX Vaginal Panel (MVP; Becton, Dickinson and Company, BD Life Sciences–Diagnostic Systems) is a molecular-based assay that facilitates data analysis of target genomic sequences in BV, Candida spp, and TV following polymerase chain reaction–based detection [10] to provide vaginitis diagnostics. Another assay, the BD MAX CT/CG/TV panel (MCGT; Becton, Dickinson and Company, BD Life Sciences–Diagnostic Systems) [11], is an STI panel that detects CT, GC, and TV DNA. In this study, we assessed the utility of diagnostic testing for CT, GC, and TV from stored samples, originally collected for diagnosis of vaginitis. Because the TV DNA target is included in the MVP, we also assessed the concordance of results between the 2 panels for this pathogen.

**MATERIALS AND METHODS**

**Population and Samples**

The Standards for Reporting Diagnostic Accuracy (STARD) statement was used to ensure accurate reporting in this article [12]. The study design was a nonmatched, retrospective assessment using de-identified residual specimens from the MVP clinical study. Vaginal swab specimens were collected during the MVP study as previously described [10]. The MVP study was a diagnostic accuracy, prospective cross-sectional study. All women enrolled in the study presented with at least 1 of the following symptoms of vaginitis or BV: abnormal vaginal discharge; vaginal itching; painful or frequent urination, irritation, or burning; painful or uncomfortable intercourse; and/or vaginal odor. All vaginitis results were known for samples prior to selection for MCGT testing.

In the parent clinical study for the MVP assay, 1740 women were enrolled [10]. From that pool, 1701 self-collected specimens were obtained that yielded reportable (positive or negative) results from the MVP. Within these specimens, 667 were positive for BV, 305 were positive for Candida spp, 303 were positive for BV and Candida spp, and 426 were negative for a vaginitis cause (Supplementary Table 1). A total of 1223 self-collected specimens were identified that produced results in the parent study for all the MVP targets. Within this group, 17 were excluded due to missing consent for use of remnant specimen and 64 specimens were excluded due to inclusion into another study. From the remaining 1142 specimens, 68 were identified as positive for TV and were included in this analysis. Following identification of the TV-positive samples, samples for analysis from vaginitis categories (BV, Candida spp, and vaginitis negative) were selected from the remaining 1074 specimens to match, as closely as possible, the positivity rates reported in the BD MAX parent study (Supplementary Table 1) [10]. The selection for BV, Candida spp, and vaginitis-negative specimens was performed in a blinded fashion (all demographic or other information unknown) using a code that randomly chose specimens based on vaginitis status. Overall, 1120 specimens were excluded and 581 specimens were included for testing with the MCGT assay.

MVP is an automated, in vitro diagnostic test on the BD MAX System. This US Food and Drug Administration–authorized molecular diagnostic assay provides qualitative (positive/negative) results for BV, Candida group (consisting of C. albicans, C. tropicalis, C. parapsilosis, and C. dubliniensis [plus C. glabrata and C. krusei separately due to potential antifungal resistance]) and TV. MVP directly detects DNA targets from pathogens associated with Candida spp and TV, and determines BV diagnosis through a bioinformatic algorithm, which detects the presence, absence, and relative load of BV markers (Lactobacillus spp [L. crispatus and L. jensenii], Gardnerella vaginalis, Atopobium vaginae, Megasphaera-1, and BV-associated bacterium 2) [10].

Samples used in this study were previously stored at –20°C prior to shipment to test sites. Testing was performed at the University of Alabama at Birmingham and at the BD diagnostics facility in Quebec City, Canada. Samples were allowed to come to room temperature, preheated according to the instrument parameters, and loaded onto the BD MAX instrument. The assay requires approximately 15 minutes of hands-on time for a run of 24 samples, and results are available in approximately 3.5 hours. All processes, including DNA extraction, reagent rehydration, amplification, and detection of target nucleic acid sequences, were handled automatically by the BD MAX instrument.

Samples were identified only with the study identification number that had been assigned during the MVP study, and no patient-specific information was provided to the testing laboratories. Institutional review board approval was obtained for this project and informed consent was performed during the MVP study with permission to use residual samples in future research [10].

**Analyses**

Although TV is a target in MVP, this pathogen is strictly transmitted through sexual contact. In the analyses presented here, “vaginitis” will be used as a term to describe the presence of BV and/or Candida spp, excluding TV. Thus, “BV only,” “Candida only,” “BV and Candida,” or “no vaginitis” represent 4, mutually exclusive categories in which TV may or may not be present. All TV infections are described as STI. Demographic data, including age and symptoms reported, were analyzed in the context of infection variables to characteristics of patients with infections.
Positivity rates of CT, GC, and TV were calculated based on the MCGT results. Odds ratios (ORs) were determined along with their asymptotic confidence intervals (CIs). Fisher exact test was used to generate \( P \) values. The statistical difference for overall percentage agreement values was performed with the determination of the Cohen \( \kappa \) coefficient. A \( \kappa \) statistic of > 0.90 indicates almost perfect agreement between the 2 populations being studied (beyond chance) [14]. Adjusted positivity rates within MVP-tested samples were generated using weighted values. Weighted values were calculated by using the ratio of the vaginitis positivity rates in the parent study [10] to the rates in this study and using that correction factor to estimate the STI positivity rates accordingly for BV only, BV/TV, Candida spp only, Candida spp/TV, BV/Candida spp, BV/Candida spp/TV, TV only, and MVP-negative specimens. \( P \) values for adjusted positivity rates were calculated using bootstrapping. Results were considered significant at the level of \( \alpha \leq .05 \).

RESULTS

Testing was performed on 581 specimens from women who had provided specimens for the MVP study [10]. TV results were obtained from 560 of 581 (96.4%). Twenty-one specimens were removed as they did not generate reportable results from the MCGT assay. This was due either to instrumental failure or an internal control failure. The cumulative positivity rate (70.2%; Table 1) for BV and Candida spp combined was similar to the rate reported in the parent study (74.2%) [10]. This suggests that the randomization of sample selection was effective.

As shown in Table 1, the mean age for women who provided samples in this study was 28.2 years. The median age in this study was 27 years (range, 18–72 years). The mean age for the BV or Candida spp–positive group and the BV and Candida spp–negative group was 31.1 years and 29.1 years, respectively. Fifty-eight percent of the women were black, with white participants comprising 23.9% of the study population. Most of the samples were collected at family planning clinics (68.8%), whereas fewer were collected at STD/human immunodeficiency virus clinics and OB/GYN clinics (17.0% and 14.3%, respectively). In the BV and/or Candida spp–positive group, 22.4% of women were coinfected with an STI, whereas 9.0% of women who were negative for both BV and Candida spp were positive for an STI. For individual STIs, TV had a positivity rate in women with BV and/or Candida spp of 15.0%, whereas TV was present in only 6.0% of women who were negative for both

| Characteristic                  | Total (N = 560) | BV or Candida Species Positive (n = 393 [70.2%]) | BV or Candida Species Negative (n = 167 [29.8%]) |
|--------------------------------|-----------------|-----------------------------------------------|-----------------------------------------------|
| Mean age, y                     | 28.2            | 31.1                                          | 29.1                                          |
| Median age, y (range)           | 27 (19–72)      | 26 (18–70)                                   | 29 (18–72)                                   |
| Race                            |                 |                                               |                                               |
| Black/African American           | 58 (325)        | 65.4 (257)                                   | 40.7 (68)                                    |
| White                           | 23.9 (134)      | 19.3 (76)                                    | 34.7 (58)                                    |
| Other                           | 18.0 (101)      | 15.3 (60)                                    | 24.6 (41)                                    |
| Ethnicity                       |                 |                                               |                                               |
| Hispanic/Latino                 | 8.2 (46)        | 6.9 (27)                                     | 11.4 (19)                                    |
| Non-Hispanic                    | 91.8 (514)      | 93.1 (366)                                   | 88.6 (148)                                   |
| Clinic type                     |                 |                                               |                                               |
| STD/HIV                        | 170 (95)        | 18.6 (73)                                    | 13.2 (22)                                    |
| Family planning                 | 68.8 (385)      | 73.0 (287)                                   | 58.7 (98)                                    |
| OB/GYN                          | 14.3 (80)       | 8.4 (33)                                     | 28.1 (47)                                    |
| Symptoms                        |                 |                                               |                                               |
| Abnormal vaginal discharge      | 75.9 (425)      | 79.1 (311)                                   | 68.3 (114)                                   |
| Painful/frequent urination      | 11.6 (65)       | 9.4 (37)                                     | 16.8 (28)                                    |
| Vaginal itching/burning/irritation | 48.2 (270)    | 46.1 (181)                                   | 53.3 (89)                                    |
| Painful/uncomfortable intercourse | 10.2 (57)    | 8.1 (32)                                     | 15.0 (25)                                    |
| Vaginal odor                    | 48.9 (274)      | 575 (226)                                    | 28.7 (48)                                    |
| STI result                      |                 |                                               |                                               |
| Any STI positive                | 18.4 (103)      | 14.9                                         | 22.4 (88)                                    |
| CT positive                     | 6.1 (34)        | 6.1                                          | 7.9 (31)                                     |
| GC positive                     | 1.8 (10)        | 1.7                                          | 2.0 (8)                                      |
| TV positive                     | 12.3 (69)       | 8.3                                          | 15.0 (59)                                    |

Data are presented as % (No.) unless otherwise indicated.

Abbreviations: BV, bacterial vaginosis; CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae (gonococcus); GYN, gynecology; HIV, human immunodeficiency virus; OB, obstetrics; STD, sexually transmitted disease; STI, sexually transmitted infection; TV, Trichomonas vaginalis.
vaginitis causes. CT had positivity rates of 7.9% and 1.8%, and GC had positivity rates of 2.0% and 1.2%, in women with or without a vaginitis diagnosis, respectively.

Of the 560 specimens with TV reportable results, 557 had reportable results for all 3 targets on the MCGT assay. Of those 557 specimens, 39.7% (221/557) tested positive for CT, 2.0% and 1.2%, in women with or without vaginitis, respectively. CT had positivity rates of 7.9% and 1.8%, and GC had positivity rates of 2.0% and 1.2%, in women with or without vaginitis, respectively.

Because the selection algorithm for TV-positive specimens (ie, all available TV-positive samples were chosen for analysis), weighted positivity rates for CT remained significantly more common among women with TV compared to women with BV (with or without Candida spp) compared to women with no vaginitis with P values < .05. This held true for the comparison of any STI among women with BV (with or without Candida spp) compared to women without vaginitis with P values < .05. However, for TV as a cause of STI, the weighted positivity rates were no longer statistically different for women with BV (with or without Candida spp) compared to those with no vaginitis (Table 2).

Because TV infections can be detected by either the MVP or the MCGT assay, we wanted to assess the comparability of the test results across platforms. From the 560 specimens that provided a reportable result for TV by both assays, only 1 discrepant result (positive on the MCGT assay and negative on MVP) was identified (Supplementary Table 2). The percentage agreement among the 2 assays was 99.8% (95% CI, 99.0%–100%), with a κ score of 0.99 (95% CI, 0.98–1.00).

### Table 2. Concomitant Sexually Transmitted Infection and Vaginitis Diagnoses

| Species     | TV Positive | TV Positive, % | 95% CI | TV Positive, % | 95% CI | TV Positive, % | 95% CI |
|-------------|-------------|----------------|--------|----------------|--------|----------------|--------|
| CT          | 19.0        | 14.4           | 9.4–22.2| 20.8           | 15.5–26.0| 18.0           | 12.4–23.6|
| GC          | 9.2         | 6.9            | 3.1–13.9| 9.2            | 7.0–12.3| 6.8            | 3.9–10.7 |
| Any STI     | 24.4        | 19.6           | 11.3–30.5| 20.8           | 15.5–26.0| 18.0           | 12.4–23.6|

Data are presented as % (95% confidence interval) unless otherwise indicated. For this analysis, TV was categorized as a sexually transmitted infection rather than a cause of vaginitis. Prevalences were adjusted by weighting to control for the inclusion of TV-positive samples from the parent study.

Abbreviations: BV, bacterial vaginosis; CT, Chlamydia trachomatis; GC, gonococcus; TV, Neisseria gonorrhoeae; STI, sexually transmitted infection; MVP, Multistate Vaginitis Panel; MCGT, Multiplex Card-based Genital Tract Infection Test.
Results from the MCGT and MVP assays were also analyzed according to clinic type in this study. We characterized the participating sites in this study as OB/GYN, family planning, or STD clinics. As shown above (Table 1), the majority of specimens were collected at family planning clinics. In the subset of samples used in this analysis, the proportion of participants originally recruited from STD (18.9%) and non-STD (81.1%) clinics was similar to the proportion in the parent study. For the current analysis involving MVP results, we found that a significantly higher proportion of BV-positive samples, compared to total results, were identified at STD (69.5%) clinics compared with non-STD (56.1%) clinics ($P = .0166$; Table 4). For *Candida* spp, no difference in the proportion of positive results was found based on clinic types at which the women were recruited. This distribution of causes of vaginitis across clinic types was similar to the distribution seen in the parent study as well. For STI results, a significantly higher proportion of CT results was obtained from STD clinics compared with non-STD clinics (11.6% vs 4.9%, respectively; $P = .03$). This was also the case for TV results (27.4% vs 9.2%; $P < .001$). While STI positivity was highest in the STD clinic population, the positivity rates of CT, GC, and TV (4.9%, 1.3%, and 9.2%, respectively) found among women attending non-STD clinics were higher than the national average prevalence rates [15].

**DISCUSSION**

The BD MAX system facilitates the detection of numerous vaginitis-causing pathogens, including BV, *Candida* spp, CT, GC, and TV, from 1 collected specimen. Here we show that a large percentage (>85%) of individuals positive for any STI were also positive for BV or *Candida* spp. Women who were positive for BV were significantly more likely to have a CT infection, a TV infection, or any STI, regardless of clinic type. This is important as non-STD clinic types had high positivity rates for STI. In addition, while BV positivity rates in the parent study were high in non-STD clinics (53.5%), the rates were even higher in STD clinics (74.5%). These current data, in combination with previous work [10, 16], suggest that it is common for women to have multiple pathogens that may play a role in vaginitis (including STI); therefore, accurate and comprehensive diagnostic testing is critical to ensure appropriate treatment of patients. Clinical diagnosis that determines only a single pathogen or syndrome is likely underdiagnosing STI infections that require different clinical management.

TV is a pathogen that is included in the MVP and is strongly associated with the presence of BV. Importantly, the MVP and MCGT assays have a high degree of concordance for the detection of TV, which should allow accurate and sensitive detection of this vaginitis-causing agent, regardless of the clinic type in which patients are seen. However, additional testing is warranted among women presenting with symptoms of vaginitis

### Table 3. Likelihood of Sexually Transmitted Infections Among Women With Bacterial Vaginosis or *Candida* Species

|                | MVP |                  |                  | Positive (n = 171) | Negative (n = 386) | OR (95% CI) | P Value |
|----------------|-----|------------------|------------------|-------------------|-------------------|-------------|---------|
| MCGT CT positive | 8.3 (27) | 3.0 (7) | 2.9 (1.2–6.8) | 0.0114 |
| MCGT GC positive | 2.1 (7)   | 1.3 (3)   | 1.7 (1.4–6.6) | 0.5343 |
| MCGT TV positive | 17.5 (57) | 3.9 (9) | 5.2 (2.9–10.8) | <0.0001 |
| Any STI positive | 24.8 (81) | 8.2 (19) | 3.7 (2.2–6.3) | <0.0001 |

Data are presented as % (No.) unless otherwise indicated.  
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; CT, *Chlamydia trachomatis*; GC, *Neisseria gonorrhoeae* (gonococcus); MCGT, BD MAX CT/GC/TV panel; MVP, BD Max Vaginal Panel; OR, odds ratio; STI, sexually transmitted infection; TV, *Trichomonas vaginalis*.
and testing positive for TV. Among the 68 women identified as positive for TV using the MVP assay, only 6 were coinfected with another STI (1 with GC, 4 with CT, and 1 with CT and GC; Supplementary Table 1). Therefore, use of a positive TV result to indicate the need for additional STI testing would have missed the remaining 29 CT and 8 GC infections identified through dual testing as these were from TV-uninfected women. Furthermore, given the significant association of a BV- and/or Candida spp–positive result with CT infection (compared to vaginitis-negative women), reflex testing for STI only in vaginitis-negative specimens would likely be an ineffective strategy for identifying all infections. These conclusions are clinically relevant given that different oral antibiotic treatment regimens exist for TV that may or may not effectively treat BV, and that CT and GC infections would not be covered by therapies commonly used to treat any of the MVP targets [17].

In the United States and many industrialized countries that collect surveillance data, the rates of all STIs continue to increase despite long-standing recommendations for annual screening among women <25 years of age [8]. The best measure of US screening rates is provided annually by the Health Education Data Information System. Available data indicate that only 50% of women in the recommended age range are screened each year [18]. Screening most often occurs at federally funded STD clinics, family planning clinics, and OB/GYN and primary care practices [19]. As federal funding for the first 2 clinic types decreases, the burden of testing is shifting to OB/GYN and primary care practices where women are more often assessed for vaginitis to the exclusion of STI screening. In this scenario, molecular testing represents an efficient, sensitive, accurate, and objective test that can be performed for all causes of vaginitis.

This study has limitations that should be noted. First, the MCGT assay was performed on frozen remnant specimens enrolled during the MVP study [10]; the specimens were tested beyond the 30-day stability period that is claimed by the BD MAX UVE Specimen Collection Kit. Second, the samples were chosen to include all available TV-positive specimens (as determined from the MVP study) to determine concordance between the MVP and MCGT assays. As a result, the distribution of TV in the study population (approximately 11%) is not truly representative of that previously published (8.3%) [10]. Indeed, adjustment for specimen collection procedures resulted in a reduced prevalence value for TV as an STI cause in the BV and BV/Candida spp vaginitis populations. Finally, the low numbers of GC-positive samples limited our statistical power for comparison of STI rates in vaginitis-positive and -negative groups for this pathogen.

CONCLUSIONS

As women are seen in different clinical settings for symptoms indicative of vaginitis, it is important for treating clinicians to be aware that women with symptoms of vaginitis could be at an increased risk for an STI. The increased risk of some STIs in women who are positive for BV or Candida spp provides a strong impetus for comprehensive testing for STI. Integration of molecular testing for vaginitis and STI would establish consistent, objective, and sensitive testing methods [10], regardless of clinic type, to accurately identify and treat patients for these conditions.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Author contributions. All authors contributed to the interpretation of the data, critically revised the manuscript for important intellectual content, approved the final version to be published, and agree to be accountable for all aspects of the work. BD employees, who are also authors, played the following roles during the study and development of the paper: S. P. facilitated data acquisition and interpretation, drafting, and revision of the manuscript; S. K. facilitated conception and design of the study, data acquisition and interpretation, and drafting and revision of the manuscript; C. C. facilitated study conception and design, and manuscript revision. These 3 authors provided final approval of the manuscript and agree to be accountable for the accuracy and integrity of this work.

Acknowledgments. The authors thank Nicholas Healy, MS, Devin S. Gary, PhD, and Jeff Andrews, MD, FRCS (all from Becton, Dickinson and Company, BD Life Sciences–Diagnostic Systems) for insight, discussion, and review during the preparation of this manuscript. The authors also thank Christina Chiao of Becton, Dickinson and Company, BD Life Sciences–Diagnostic Systems, for statistical support.

Financial support. This work was supported by Becton, Dickinson and Company, BD Life Sciences–Diagnostic Systems, Sparks, Maryland.
Potential conflicts of interest. B. V. D. P. received institutional research support, honoraria, or consulting fees from Becton, Dickinson and Company, Atlas Genetics, Beckman Coulter, Click Diagnostics, Hologic, LumineX, Roche, SpeeDx, Cepheid, Click Diagnostics, and Abbott Molecular. S. P., S. K., and C. K. C. are employees of Becton, Dickinson and Company, the sponsor of the study. G. D. reports no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med 1998; 13:335–46.
2. Egan ME, Lipuky MS. Diagnosis of vaginitis. Am Fam Physician 2000; 62:1095–104.
3. Centers for Medicare and Medicaid Services. Provider performed microscopy (PPM) procedures. 2016; 42 CFR Section 493.19.
4. Wiesenfeld HC, Macio I. The infrequent use of office-based diagnostic tests for vaginitis. Am J Obstet Gynecol 1999; 181:39–41.
5. Van Der Pol B. Sexually transmitted infections in women. Scand J Clin Lab Invest Suppl 2014; 244:68–74; discussion 73.
6. Kouvans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007; 34:864–9.
7. Kissinger P. Epidemiology and treatment of trichomoniasis. Curr Infect Dis Rep 2015; 17:484.
8. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
9. Belley-Montfort L, Lebed J, Smith R, et al. Sensitivity of the Amsel's criteria compared to the Nugent score in absence and in presence of Trichomonas vaginalis (TV) and/or Candida spp. among women with symptomatic vaginitis/vaginosis (abstract). Sex Transm Infect 2015; 91:A97.
10. Gaydos CA, Beqaj S, Schweber JR, et al. Clinical validation of a test for the diagnosis of vaginitis. Obstet Gynecol 2017; 130:181–9.
11. Van Der Pol B, Williams JA, Fuller D, Taylor SN, Hook EW 3rd. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD max CT/GC/TV assay with genitourinary specimen types. J Clin Microbiol 2017; 55:155–64.
12. Bossuyt PM, Reitsma JB, Bruns DE, et al; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 2015; 277:826–32.
13. Fleiss JL, Cohen J, Everitt BS. Large sample standard errors of kappa and weighted kappa. Psychol Bull 1969; 72:323–7.
14. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012; 22:276–82.
15. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40:187–93.
16. Bautista CT, Wurapa EK, Sateren WB, Morris SM, Hollingsworth BR, Sanchez JL. Association of bacterial vaginosis with chlamydia and gonorrhea among women in the U.S. Army. Am J Prev Med 2017; 52:632–9.
17. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1–137.
18. Khosropour CM, Broad JM, Scholes D, Saint-Johnson J, Manhart LE, Golden MR. Estimating chlamydia screening coverage: a comparison of self-report and health care effectiveness data and information set measures. Sex Transm Dis 2014; 41:665–70.
19. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2016. Atlanta: US Department of Health and Human Services, 2017.